Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach.

BORIS DOI
Publisher DOI
PubMed ID
38263431
Date of Publication
2024-02
Publication Type
Article
Subject(s)
Language(s)
en
Contributor(s)
Dengjel, Jörn
Davies, Andrew
Additional Credits
Series
Leukemia
Publisher
Nature Publishing Group
ISSN
0887-6924
Access(Rights)
open.access
Show full item